HotSpot Therapeutics to Present Preclinical Data from Small Molecule IRF5 Inhibitor Program at 15th European Lupus Meeting
BOSTON, Feb. 26, 2026 /PRNewswire/ -- HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of oral, allosteric...
Read moreDetails